CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
CytomX Therapeutics (NASDAQ:CTMX) Full Year 2023 Results
Key Financial Results
Revenue: US$101.2m (up 90% from FY 2022).
Net loss: US$569.0k (loss narrowed by 99% from FY 2022).
US$0.008 loss per share (improved from US$1.51 loss in FY 2022).
CTMX Products In Clinical Trials
Phase I: 1.
Phase II: 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
CytomX Therapeutics Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) missed analyst estimates.
Looking ahead, revenue is expected to decline by 13% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 17%.
Performance of the American Biotechs industry.
The company's shares are down 21% from a week ago.
Risk Analysis
You should learn about the 5 warning signs we've spotted with CytomX Therapeutics (including 2 which are a bit concerning).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
